Is mean platelet volume itself a sufficient indicator of coronary syndrome X? by Bugan, Baris & Onar, Lutfi Cagatay
Is mean platelet volume itself a sufficient indicator of
coronary syndrome X?
Baris Bugan,I Lutfi Cagatay OnarII
IMalatya Military Hospital, Cardiology Service, Malatya/Turkey. IIMaltepe University Faculty of Medicine, Department of Cardiovascular Surgery, Istanbul/
Turkey.
Email: bbugan@hotmail.com
Tel.: 90 (532) 347 60 96
Dear Editor,
We read with deep interest the paper ‘‘Evaluation of the
mean platelet volume in patients with cardiac syndrome X’’
by Demirkol et al. (1). The authors (1) aimed to evaluate the
mean platelet volume (MPV) in patients with cardiac
syndrome X (CSX) and compare patients with coronary
artery disease (CAD) with a control group. We have a minor
criticism concerning their methodology.
Although statistical significance was defined as p,0.05
and the p-values of MPV were given, the p-values of all
variables should have been provided in the paper (1). It
seems that some of the variables are not compatible with a
normal distribution. However, the continuous variables
were only reported as mean¡standard deviation (SD). In
addition, the authors (1) used a one-way analysis of
variance (ANOVA) or Kruskal–Wallis test to compare the
variables. ANOVA is used to analyze the means of two or
more samples. The Kruskal–Wallis test is the nonparametric
equivalent of the ANOVA test. The statistical test used for
each variable in the study is thus unclear (1).
CSX is an angina with signs associated with decreased
blood flow to the heart tissue but with normal coronary
arteries. A number of systemic microvascular abnormalities,
including endothelial cell dysfunction, diffuse atherosclero-
sis, and systemic inflammation, result in reduced blood flow
(2,3). Platelets play a key role in atherothrombosis and
inflammation. MPV, an index of platelet function, is a
potential marker of platelet reactivity. Therefore, recent
studies have focused on platelet function and inflammatory
markers to determine their importance in cardiovascular
diseases, including CSX (4,5). Most conditions, including
traditional risk factors (e.g., hypertension, atherogenic
lipoproteins, obesity, and hyperglycemia) and many inflam-
matory conditions (e.g., infection and inflammatory dis-
eases), can influence MPV (4,5). However, the authors (1)
did not exclude local or systemic infections or any previous
history of infection (particularly ,3 months).
In addition, the authors (1) did not analyze inflammation
markers, such as C-reactive protein (CRP), even though
their role in inflammation has been previously reported in
CAD. It is still unclear whether MPV measurement is the
best method to determine the inflammation in patients with
CSX. If other proven inflammatory markers (in addition to
MPV) had been screened and were found to correlate with
the MPV of these patients, the conclusions would have been
more definitive. Therefore, the MPV should be evaluated
together with the other serum inflammatory markers.
Although the authors (1) did not include other markers
relevant to CSX in their paper, we agree with their follow-
up letter that suggests that MPV itself (without other
inflammatory markers) may not provide comprehensive
information about ongoing inflammation (6). Furthermore,
in addition to the p values, the exact MPV values for each
group should have been provided in order to analyze the
entire study group to determine the clinical impact of the
MPV.
We would like to congratulate the authors (1) for
highlighting the efficacy of MPV in patients with CSX.
MPV appears to be a novel marker and an important
indicator and predictor of atherothrombosis together with
traditional risk factors and other proven inflammatory
markers. Large-scale prospective clinical studies with these
recommendations are now needed.
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